Background: This Australian single-arm, multicenter, phase II trial evaluated feasibility, tolerability and activity of accelerated bleomycin, etoposide and cisplatin (BEP) as first-line chemotherapy for metastatic germ cell tumours.
introduction
Germ cell tumours (GCTs) are the most common malignancy affecting adolescent and young adult males in Western countries [1] . Outcomes are excellent for most patients, but cure rates for patients with advanced disease and intermediate or poor prognostic features are only 79% and 48%, respectively [2] .
There have been no further improvements in the efficacy of first-line chemotherapy since the introduction of BEP (bleomycin, etoposide, cisplatin) in the mid-1980s. Four cycles of BEP given every 3 weeks remain the internationally accepted, standard of care for intermediate-and poor-prognosis patients [3] , and three cycles of BEP given every 3 weeks [4] is the most commonly endorsed regimen for good-prognosis patients [5] .
Previous strategies to improve first-line chemotherapy tested in phase II and III clinical trials have included the use of alternative or additional chemotherapy agents, more complex multidrug regimens, and very high-dose chemotherapy with stem cell support . Unfortunately, none of these strategies have improved cure rates, and all are more toxic than BEP [3] .
Shortening the time between treatment cycles may increase the sensitivity of tumours to chemotherapy by overcoming accelerated repopulation, and is feasible with the use of granulocyte colony-stimulating factor (G-CSF) which reduces the duration of leukopenia [6] . Accelerating chemotherapy by cycling 2-weekly rather than 3-weekly has increased cure rates without significant additional toxicity in other cancers, including lymphoma (before introduction of rituximab) [7, 8] , breast cancer [9] and Ewing's sarcoma [10] . Additional benefits of accelerated regimens are that they are completed sooner, so may be preferable to patients and improve compliance [11] , and incur minimal additional financial cost beyond administration of G-CSF.
The aim of this study was to pilot an accelerated regimen of BEP that could later be compared with standard BEP in an international, randomised trial.
patients and methods

patient population
Eligible participants were aged between 18 and 40 years with GCT (nonseminoma or seminoma) arising in the testis, retroperitoneum, mediastinum or ovary. Histological confirmation was required, except for male patients with an appropriate clinical picture and a clinical need to start chemotherapy urgently.
Patients were further required to have metastatic disease; of any International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic group [2] , or similar parameters for patients with ovarian primaries; with radiologically measurable disease; absolute neutrophil count (ANC) ≥ 1.0 × 10 9 /l; platelet count ≥100 × 10 9 /l; bilirubin ≤ 1.5 × ULN; ALT and ALP ≤ 2.5 × ULN, except if the elevations were due to metastatic disease; and GFR ≥ 60 ml/min.
Patients were excluded if they had a previous malignancy (other than germ cell malignancy or non-melanoma skin cancer), previous chemotherapy or radiotherapy (except patients with pure seminoma relapsing after radiotherapy), peripheral neuropathy ≥grade 2, or clinically significant hearing loss or tinnitus.
All patients provided written, informed consent. The study was approved by the Human Research Ethics Committees at all participating centers.
treatment regimen
Patients were panned to receive accelerated BEP chemotherapy, consisting of bleomycin 30 000 international units (i.e. 30 mg) IV weekly; etoposide 100 mg/m 2 IV on days 1, 2, 3, 4, 5; cisplatin 20 mg/ m 2 IV on days 1, 2, 3, 4, 5 and pegylated G-CSF ( pegfilgrastim, Neulasta) 6 mg administered on day 6. For patients with intermediate-or poor-prognosis disease, treatment was repeated every 2 weeks for four cycles, and bleomycin was administered to a maximum of 12 doses. For patients with good-prognosis disease, treatment was repeated every 2 weeks for three cycles, and bleomycin was administered to a maximum of nine doses. Accelerated BEP is compared with standard BEP in supplementary Figure S1 , available at Annals of Oncology online. Chemotherapy was delayed on day 15 for up to 1 week if the ANC was <1.0 × 10 9 /l and/or the platelet count was <100 × 10 9 /l, and until any grade 3-4 mucositis or diarrhoea had recovered. Etoposide dose was to be reduced by 20% for all subsequent cycles if the patient developed thrombocytopenic bleeding (with platelet count <20 × 10 9 /l), or a prolonged episode of febrile neutropenia (defined as fever >38.5 degrees Celsius and neutrophils <0.5 × 10 9 /l for ≥5 days) in the previous cycle. Consistent with the standard Australian practice, bleomycin was to be omitted if there was unexplained and significant dyspnoea, cough or basal crepitations; unexplained radiological changes on chest X-ray (CXR) consistent with bleomycin toxicity; >25% reduction from baseline in diffusing capacity of lung for carbon monoxide (DLCO) adjusted for haemoglobin, and/or vital capacity. The patient was to be removed from protocol treatment if the estimated GFR fell and remained <35 ml/min despite intravenous hydration.
subsequent treatment
If patients with poor-prognosis disease had bleomycin ceased because of pulmonary toxicity, and less than eight doses of bleomycin had been administered, then etoposide, ifosfamide, cisplatin (VIP) chemotherapy was to be substituted for the remaining cycles.
Following chemotherapy, it was recommended for patients with nonseminoma that all residual masses >1 cm on computed topography (CT) should be resected whenever possible. The recommended policy for nonprogressing residual masses after chemotherapy for pure seminoma was observation alone.
assessments and follow-up
Monitoring during and at the completion of study treatment included weekly blood tests; and second-weekly lung function tests, CXR and patientrated neurotoxicity using the FACT/GOG-Ntx version 4 [12] . Patients were then followed every 3 months for the first 2 years, every 6 months for the subsequent 3 years, then yearly on an ongoing basis. Adverse events were recorded according to the criteria of the National Cancer Institute Common Terminology for Adverse Events v3.0 [13] .
statistical methods
The primary end point for this phase II study was feasibility of the regimen, defined as the proportion of patients able to complete the etoposide and cisplatin components of BEP and be eligible to start a fourth cycle of BEP within 50 days of their first dose of chemotherapy, i.e. with a delay of no more than 7 days. Non-protocol-guided modifications were not to be counted as successes. Secondary end points included adverse events, continuous complete remission at 12 months, progression-free and overall survival, the relative dose intensity of treatment compared with standard BEP, effects on lung function and patient-rated neurotoxicity.
Continuous complete remission at 12 months required disease status of complete response (CR) to chemotherapy +/− surgery for non-seminomas; and CR or residual, non-progressive marker-negative radiologic abnormalities for pure seminomas. Complete resection of viable GCT was considered CR to chemotherapy + surgery. The relative dose intensity was calculated by dividing the actual mean dose ( per week) of drug delivered in the study, by the mean dose ( per week) of drug delivered in the standard BEP regimen. The planned relative dose intensity for cisplatin and etoposide was 1.5, and for bleomycin it was 1.0. Total scores for patient-rated neurotoxicity were the sum of the scores for the individual scales, and ranged from 0 (none) to 44 (worst).
The initial sample size of 25 patients assumed that the study regimen was feasible if ≥90% achieved the primary end point, but not ≤67%. Using Simon's two-stage mini-max design with a one-sided type error rate of 5% and 90% power, the trial was to be stopped if ≤11 of the first 16 patients achieved the primary end point. If ≥12 achieved the primary end point, then at least another nine patients. The regimen was to be deemed feasible if at least 21 of the 25 patients (≥84%) achieved the primary end point, after Figure S2 , available at Annals of Oncology online for the study CONSORT diagram).
feasibility of treatment
The study met its primary end point at both pre-planned analyses and the final analysis, as defined prospectively. The regimen was deemed to be feasible in 37 of 43 patients (86%, 95% CI 72% to 95%), inevaluable in three patients (7%) and not feasible in three patients (7%) ( Table 3, supplementary Table S1 , available at Annals of Oncology online). One patient was withdrawn from the study, and subsequently completed cisplatin-based chemotherapy off study. Two patients with intermediate prognosis were accidentally treated as goodprognosis patients and only received three cycles of etoposide and cisplatin. All other patients received all doses of etoposide and cisplatin. Twenty-one of 43 patients (49%) received all planned bleomycin doses, 9 patients (21%) received at least two-thirds but less than all planned doses and 13 patients (30%) received less than two-thirds of planned doses. Bleomycin was withheld in all cases because of asymptomatic decline in DLCO. Omission of bleomycin for alteration in DLCO was not considered a failure for the primary end point of feasibility. Further details are given in supplementary Table S1 and Figure S2 , available at Annals of Oncology online.
dose-intensity of treatment
The mean achieved dose intensity was 48 mg/m 2 /week for cisplatin, and 247 mg/m 2 /week for etoposide. The mean achieved relative dose intensity compared with standard BEP is given in supplementary Table S1 , available at Annals of Oncology online.
adverse events and effects on lung function
Adverse events are summarised in Table 2 and supplementary  Table S2 , available at Annals of Oncology online. There were no deaths attributed to protocol treatment. Effects on lung function are shown in Table 2 . Asymptomatic declines in DLCO were common; however, there were no cases of clinical lung toxicity or radiologic evidence of lung toxicity.
efficacy
Responses to treatment; and rates of continuous complete remission at 12 months, progression-free survival and overall survival are detailed in Table 3 and supplementary Figure S3 , available at Annals of Oncology online. Characteristics of patients who underwent surgery are shown in supplementary  Table S4 , available at Annals of Oncology online. Patients who received less than full doses of bleomycin had worse outcomes if they were of good or poor prognosis, but better outcomes if they were of intermediate prognosis (supplementary Table S3 , available at Annals of Oncology online).
After a median follow-up of 27 months (range 6-42 months), 8 of 43 patients have progressed, including all 6 with incomplete response to protocol treatment; one patient who progressed before planned resection of residual disease and is now in remission at 17 months after enrolment following salvage chemotherapy and surgery; and one patient with good prognosis disease who relapsed at 14 months from enrolment, after achieving a CR to initial therapy, and remains alive.
patient-rated neurotoxicity
Median scores for patient-rated neurotoxicity progressively worsened from baseline to just after completion of protocol treatment, but returned to baseline by 6 months following completion of chemotherapy (supplementary Figure S4 , available at Annals of Oncology online). There was a persistent deterioration of ≥5 points on the scale from 0 to 44 in 32% of patients at 6 months and 20% of patients at 12 months (complete data available for 31 and 30 patients at each timepoint).
discussion
This single-arm trial has successfully piloted an accelerated regimen of BEP chemotherapy for patients with metastatic germ cell tumours. The chemotherapy regimen was feasible to deliver in at least 86% of eligible patients, and rates of adverse events were no worse than expected for standard BEP chemotherapy. Rates of CR and progression-free survival at 2 years for accelerated BEP compare favourably with results for standard BEP in recently reported randomised trials [14] [15] [16] [17] [18] (supplementary  Table S5 , available at Annals of Oncology online).
We found that toxicities were generally no worse than those seen for standard BEP in recently reported randomised trials incorporating this regimen (supplementary Table S5 , available at Annals of Oncology online). Neutropenia was not worse than expected, despite theoretical concerns that pegfilgrastim administration on day 6 of a 14-day cycle might worsen subsequent myelosuppression [19] . Similarly, neurotoxicity and nephrotoxicity were not worse than expected despite accelerating cisplatin. No patients developed clinical evidence of bleomycin-induced lung toxicity.
Of concern, a quarter of the patients in our trial had at least one-third of planned doses of bleomycin withheld due to asymptomatic declines in DLCO, which could reduce the efficacy of the regimen. The effects on DLCO and bleomycin delivery in our trial do not differ significantly from the literature [20, 21] , and the ability to deliver bleomycin without lung toxicity in the related UK trial of accelerated BEP which did not withhold bleomycin for asymptomatic decline in DLCO are reassuring [22] . DLCO is not a reliable predictor of bleomycin lung toxicity [20, 23] , and we feel our current Australian practice of withholding bleomycin for an asymptomatic 25% reduction in DLCO may be too cautious a threshold. Strengths of our trial include the novelty of and strong rationale for the regimen, the ease of recruiting 43 eligible patients over two years, the excellent compliance of patients and investigators with the protocol regimen and follow-up, and the demonstrated feasibility of the regimen. The main limitation of the trial is its single-arm design, designed to guide further research, not to determine if accelerated BEP is more effective than standard BEP. Protocol violations may have increased toxicity and compromised efficacy. Longer follow-up is required to demonstrate more robust outcomes and exclude any unexpected late toxicities. Finally, the tolerability and efficacy of the regimen may have been exaggerated by excluding older patients and poor risk patients with organ dysfunction. Patients aged over 40 were excluded to minimise risk of additional pulmonary toxicity with more intensive use of G-CSF [23] . Patients with impaired organ function were not felt appropriate for a previously untested intensive regimen. In addition, we excluded patients aged under 18 because of regulatory and ethical constraints, and because paediatric GCTs may have different biology.
Accelerated BEP chemotherapy was safe, feasible and active. On the basis of our results and those from the related UK study, we are commencing a randomised trial of accelerated versus standard BEP for intermediate-and poor-prognosis disease. Other potential experimental treatment arms being considered by the international germ cell research community include TIP [24] , CBOP/BEP [25] , and a dose-dense regimen currently being evaluated in a French randomised phase 2 trial.
supplementary data
Supplementary Table S1-S5, and Supplementary Figures 1-4 , available at Annals of Oncology online. All had non-seminoma histology. One progressed 4 months after enrolment and before planned resection of residual disease. One had an incompletely resected retroperitoneal mass, but was subsequently designated with no evidence of disease. Three patients were observed contrary to the protocol-two were subsequently designated with no evidence of disease; one with pulmonary and hepatic metastases has shrinking residual disease.
e All six had non-seminoma histology, and all failed to normalise tumour markers with protocol treatment. Three are now without evidence of disease at 21, 31 and 36 months after enrolment following second-line chemotherapy with paclitaxel, ifosfamide, cisplatin (TIP). Three had progressive disease during or soon after completion of protocol treatment-two received second-and third-line chemotherapy without subsequent cure, of whom one has died; one declined second-line chemotherapy and further follow-up. f Death due to disease progression.
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